Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1084-1091

  Sy, Sherwin K B ^a   Innes, Steve ^b   Derendorf, Hartmut ^a   Cotton, Mark F ^b   Rosenkranz, Bernd ^c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; STAVUDINE; STAVUDINE TRIPHOSPHATE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHILD; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOCHONDRIAL TOXICITY; PRIORITY JOURNAL; SIMULATION;

ADULT; ANTI-HIV AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MITOCHONDRIA; MODELS, STATISTICAL; STAVUDINE;

EID: 84893485439     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01717-13     Document Type: Article

References (38)

1. Lallemant M, Chang S, Cohen R, Pecoul B. 2011. Pediatric HIV-a neglected disease? N. Engl. J. Med. 365:581-583. http://dx.doi.org/10.1056/NEJMp1107275.
2. Innes S, Cotton MF, Haubrich R, Conradie MM, van Niekerk M, Edson C, Rabie H, Jain S, Sun X, Zollner W, Hough S, Browne SH. 2012. High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatr. 12:183. http://dx.doi.org/10.1186/1471-2431- 12-183.
3. Innes S, Levin L, Cotton M. 2009. Lipodystrophy syndrome in HIVinfected children on HAART. S. Afr. J. HIV Med. 10:76-80. http://www.sajhivmed.org.za/ index.php/sajhivmed.
4. South African Department of Health. 2013. The South African antiretroviral treatment guidelines. The South African National Department of Health, Pretoria, South Africa.
5. Technau KG, Lazarus E, Kuhn L, Abrams EJ, Sorour G, Strehlau R, Reubenson G, Davies MA, Coovadia A. 2013. Poor early virologic performance and durability of abacavir-based first-line regimens for HIVinfected children. Pediatr. Infect. Dis. J. 32:851-855. http://dx.doi.org/10.1097/INF.0b013e31828c3738.
6. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, Milinkovic A, Gatell J, Ribera E. 2007. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin. Pharmacother. 8:679-688. http://dx.doi.org/10.1517/14656566.8.5.679.
7. McComsey GA, Lo Re V III, O'Riordan M, Walker UA, Lebrecht D, Baron E, Mounzer K, Frank I. 2008. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin. Infect. Dis. 46:1290-1296. http://dx.doi.org/10.1086/529384.
8. Milinkovic A, Martinez E, Lopez S, de Lazzari E, Miro O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM. 2007. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir. Ther. 12: 407-415. http://www.intmedpress.com/ serveFile.cfm?sUID42389fbb-9eca-4a3a-a514-e0630ef9d42d.
9. Sanchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, Soriano V. 2005. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin. Trials 6:197-202. http://dx.doi.org/10.1310/ED57-EU48-RK6A-E5U0.
10. Kaul S, Kline MW, Church JA, Dunkle LM. 2001. Determination of dosing guidelines for stavudine (2=,3=-didehydro-3=-deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 45:758-763. http://dx.doi.org/10.1128/AAC.45.3.758-763.2001.
11. Kline MW, Dunkle LM, Church JA, Goldsmith JC, Harris AT, Federici ME, Schultze ME, Woods L, Loewen DF, Kaul S, et al. 1995. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 96:247-252.
12. Jullien V, Rais A, Urien S, Dimet J, Delaugerre C, Bouillon-Pichault M, Rey E, Pons G, Blanche S, Treluyer JM. 2007. Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis. Br. J. Clin. Pharmacol. 64:105-109. http://dx.doi.org/10. 1111/j.1365-2125.2007.02854.x.
13. Anderson RE, Dunkle LM, Smaldone L, Adler M, Wirtz C, Kriesel D, Cross A, Martin RR. 1995. Design and implementation of the stavudine parallel-track program. J. Infect. Dis. 171(Suppl 2):S118-S122. http://dx.doi.org/10.1093/ infdis/171.Supplement-2.S118.
14. Pollard RB, Peterson D, Hardy D, Pottage J, Murphy RL, Gathe J, Beall G, Rutkievicz V, Reynolds L, Cross AP, Dunkle LM. 1999. Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3. J. Acquir. Immune Defic. Syndr. 22:39-48. http://dx.doi.org/10.1097/00042560-199909010-00005.
15. Petersen EA, Ramirez-Ronda CH, Hardy WD, Schwartz R, Sacks HS, Follansbee S, Peterson DM, Cross A, Anderson RE, Dunkle LM. 1995. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J. Infect. Dis. 171(Suppl 2):S131-S139. http://dx.doi.org/10.1093/infdis/171.Supplement-2. S131.
16. Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, van Leeuwen R, Weverling GJ, Kunanusont C, Lange JM, Cooper DA, Phanuphak P. 2000. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. AIDS 14:1375-1382. http://dx.doi.org/10.1097/00002030-200007070-00010.
17. Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J, Jr, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L. 1997. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann. Intern. Med. 126:355-363.
18. WHO. 2007. Addendum to 2006 WHO guidelines on antiretroviral therapy for HIV infection in adults and adolescents. World Health Organization, Geneva, Switzerland.
19. ter Hofstede HJ, Koopmans PP, Burger DM. 2008. Stavudine plasma concentrations and lipoatrophy. J. Antimicrob. Chemother. 61:933-938. http://dx.doi.org/10.1093/jac/dkn041.
20. Becher F, Landman R, Mboup S, Kane CN, Canestri A, Liegeois F, Vray M, Prevot MH, Leleu G, Benech H. 2004. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 18:181-187. http://dx.doi.org/10.1097/00002030-200401230-00006.
21. Dudley MN, Graham KK, Kaul S, Geletko S, Dunkle L, Browne M, Mayer K. 1992. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166:480-485. http://dx.doi.org/10.1093/infdis/166.3. 480.
22. Innes S, Norman J, Smith P, Smuts M, Capparelli E, Rosenkranz B, Cotton M. 2011. Bioequivalence of dispersed stavudine: opened versus closed capsule dosing. Antivir. Ther. 16:1131-1134. http://dx.doi.org/10.3851/IMP1876.
23. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL. 2002. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat. 11 11:1-190.
24. Hurwitz SJ, Schinazi RF. 2011. In silico study supports the efficacy of a reduced dose regimen for stavudine. Antivir. Ther. 92:372-377.
25. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, Markowitz M, Kost R, Hurley A, Weinberger L, Cesar D, Hellerstein MK, Ho DD. 2001. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J. Exp. Med. 194:1277-1287. http://dx.doi.org/10.1084/jem.194.9.1277.
26. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B. 2004. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 279:51545-51553. http://dx.doi.org/10.1074/jbc. M408573200.
27. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, McCune JM. 1999. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 5:83-89. http://dx.doi.org/10.1038/4772.
28. Balimane PV, Sinko PJ. 1999. Involvement of multiple transporters in the oral absorption of nucleoside analogues. Adv. Drug Deliv. Rev. 39:183-209. http://dx.doi.org/10.1016/S0169-409X(99)00026-5.
29. Plagemann PG, Wohlhueter RM, Woffendin C. 1988. Nucleoside and nucleobase transport in animal cells. Biochim. Biophys. Acta 947:405-443. http://dx.doi.org/10.1016/0304-4157(88)90002-0.
30. Panhard X, Legrand M, Taburet AM, Diquet B, Goujard C, Mentre F. 2007. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur. J. Clin. Pharmacol. 63:1019-1029. http://dx.doi.org/10.1007/s00228-007-0337-x.
31. Domingo P, Cabeza MC, Pruvost A, Salazar J, Gutierrez Mdel M, Mateo MG, Domingo JC, Fernandez I, Villarroya F, Munoz J, Vidal F, Baiget M. 2010. Relationship between HIV/highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin. Infect. Dis. 50:1033-1040. http://dx.doi.org/10.1086/651117.
32. Calvez V, Costagliola D, Descamps D, Yvon A, Collin G, Cecile A, Delaugerre C, Damond F, Marcelin AG, Matheron S, Simon A, Valantin MA, Katlama C, Brun-Vezinet F. 2002. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir. Ther. 7:211-218. http://www.intmedpress.com/serveFile.cfm?sUIDf8a7bf03- a413-46a2-acbd-5ac682945177.
33. Holguin A, Dietrich U, Immelmann A, Soriano V. 1998. Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group. Antivir. Ther. 3:183-186.
34. Siccardi M, Almond L, Schipani A, Csajka C, Marzolini C, Wyen C, Brockmeyer NH, Boffito M, Owen A, Back D. 2012. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. Clin. Pharmacol. Ther. 92:494-502. http://dx.doi.org/10. 1038/clpt.2012.61.
35. WHO. 2011. The treatment 2.0 framework for action: catalysing the next phase of treatment, care and support. World Health Organization, Geneva, Switzerland.
36. Puls R, ENCORE1 Study Group. 2013. 7th IAS Conf. HIV Pathog., Treat. Prevent., Kuala Lumpur, Malaysia, 30 June to 3 July 2013, abstr WELBB01.
37. Clayden P. 12 June 2012, posting date. Retrofitting for purpose: treatment optimization. HIV-HCV-TB Pipeline Report. http://www.pipelinereport. org/TOC/treatment-optimization.
38. Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C. 2012. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect. Dis. 12:550-560. http://dx.doi.org/10.1016/S1473-3099(12)70134-2.